Among 14 BRCA1/2 mutation carriers with CBC recurrence, 11 patients (78.6%) had recurred triple-negative type breast cancer and 10 patients (71.4%) resumed chemotherapy. This evidence concerns the gene BRCA1 and complete blood cell count.